{"id":"W2955160320","doi":"10.1200/jco.2013.31.15_suppl.531","title":"Phase II randomized study of the EGFR, HER2, HER3 signaling inhibitor AZD8931 in combination with anastrozole (A) in women with endocrine therapy (ET) naive advanced breast cancer (MINT).","year":2013,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Advanced Breast Cancer Therapies","field":"Medicine","cited_by":19,"is_retracted":false,"has_abstract":true,"ca_institutions":"Ottawa Hospital; Jewish General Hospital","funders":"","keywords":"Medicine; Anastrozole; Internal medicine; Clinical endpoint; Breast cancer; Population; Interim analysis; Oncology; Placebo; Cancer; Gastroenterology; Randomized controlled trial; Tamoxifen; Pathology","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.002115131,0.00177077,0.002852248,0.0005025635,0.0004509599,0.0008819376,0.001117483,0.001607917,0.00604663],"category_scores_gemma":[0.002127539,0.0009086342,0.001380969,0.0004500735,0.001333028,0.001219654,0.0005777279,0.003053488,0.001140589],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0009012625,"about_ca_system_score_gemma":0.001662577,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0009239972,"about_ca_topic_score_gemma":0.002241719,"domain_scores_codex":[0.999189,0.0004825018,0.0000385107,0.0001223445,0.00005441309,0.0001132685],"domain_scores_gemma":[0.9985734,0.0003296176,0.0003283918,0.0001227428,0.00007695497,0.000568878],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.9744284,0.01326188,0.0006618671,0.0001456895,0.0003483676,0.00002860072,0.00003553647,0.0002452933,0.002742645,0.0000588964,0.0004887179,0.007554145],"study_design_scores_gemma":[0.8723769,0.1246321,0.001507686,0.000008495063,0.0002160904,0.00002786832,0.00001411999,0.0002999284,0.0004016267,0.00008702072,0.0004184813,0.000009741272],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9840995,0.001755153,0.001014883,0.0007470817,0.0004989696,0.00822782,0.00189543,0.0001482985,0.001612776],"genre_scores_gemma":[0.9819495,0.001279776,0.002228379,0.00109404,0.0004217421,0.008236111,0.001660075,0.00002807125,0.003102364],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.00604663,"threshold_uncertainty_score":0.02022797,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.03122237568613488,"score_gpt":0.4148741344509979,"score_spread":0.383651758764863,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}